reSee.it - Related Video Feed

Dr. Hotez explains that while vaccines are often described as miraculous, the development was not a four-month process but a seventeen-year effort dating back to the post-SARS period. After SARS emerged in 2003, researchers identified the spike protein as the virus’s soft underbelly and began experimental vaccine development. When the COVID-19 sequence was released in January, the coronavirus community quickly concluded that a vaccine could be made, and attention turned to which technology would be fastest and most enduring. All vaccines discussed (AstraZeneca, Pfizer, Moderna, J&J, and the one being scaled in India) target the spike protein. He emphasizes that this was a deliberate long-term program, not a rushed push. Nicole notes the broader context of vaccine safety, particularly on a day when a vaccine-skeptical witness testified before the Senate Homeland Security Committee. Dr. Hotez clarifies that the virus behind the current pandemic comes from a family of coronaviruses scientists have studied for a long time, and that once specifics emerged, researchers could finalize the vaccine approach. He reiterates the importance of reassurance about safety in light of public skepticism. Dr. Hotez highlights the role of the NIH and the National Institute of Allergy and Infectious Diseases, led by Tony Fauci, and Francis Collins at NIH, in launching a major coronavirus program beginning in 2003. This funding enabled the development of some of the first prototype vaccines, illustrating a deliberate US government and NIH investment to advance vaccine research. He notes the ongoing need to assess rollout and production robustness, as this technology is brand new, and additional vaccines will be necessary to vaccinate populations. Looking ahead, the conversation acknowledges that the United States will require four or five different vaccines to achieve broad vaccination coverage, rather than relying solely on the two mRNA vaccines. The UK has begun vaccinations, marking an initial step, with plans to scale in the United States in the coming days. The discussion underscores a long road ahead to ensure scalable production, distribution, and multiple vaccine options to meet demand.

In a Phase one trial, a normal volunteer tests the safety of a potential vaccine. This process has been completed at a record speed. However, it will still take a few months to confirm its initial safety. The next step is a Phase two trial, involving hundreds or even thousands of people, which will take an additional 6 to 8 months to determine if the vaccine is effective. Overall, it will take around a year to a year and a half to know if the vaccine can be used. Another important aspect is ensuring that the vaccine does not worsen the infection. This can only be determined through extended studies involving individuals at risk. Previous cases have shown that vaccines that initially appeared safe actually made the situation worse. Therefore, caution is necessary before administering the vaccine.

The speaker emphasizes the lengthy process of developing a safe and effective vaccine, usually taking 10 to 25 years. They mention a potential safety issue with coronavirus vaccines, where immunization may lead to immune enhancement when exposed to the virus. This phenomenon has been observed in laboratory animals. Despite this concern, the speaker expresses enthusiasm for the approval of the second vaccine, stating that if enough Americans get vaccinated, virus transmission could be halted. They also mention the availability of new boosters, recommending anyone who is safe to get them for added protection.

Speaker 0 asked for the impossible: to develop a vaccine in 8 months instead of 10 years without cutting corners. They emphasized safety. Speaker 1 questioned Pfizer's transparency in mutating COVID viruses. Speaker 0 stressed the importance of vaccination for public health. Pfizer's CEO discussed vaccine production and effectiveness. They thanked the US government for support. The CEO highlighted the vaccine's 95.6% efficacy. The conversation ended with a call for public vaccination.

Vaccines are seen as magical but expectations should be tempered. Pfizer's vaccine is 95% effective, but efficacy drops over time. Boosters may be needed annually. Moderna is working on a combined flu and COVID vaccine. The future is uncertain, but we must adapt.

For the AstraZeneca vaccine, the range of efficacy in trials is based on various dosing intervals. The TGA will assess the best dosing interval for optimal efficacy in preventing severe disease. Importantly, early data suggests AstraZeneca may also effectively prevent disease transmission, which is crucial, especially for healthcare workers, in reducing outbreaks. While it's early and not peer-reviewed, there's a feeling that it significantly prevents transmission. We're still learning about the longevity of the vaccine's effects. The reported efficacy primarily focuses on preventing severe disease, where both vaccines show promise. The key is whether these vaccines prevent severe outcomes like death from COVID. Initial expectations were not necessarily to prevent infection, although there's emerging evidence suggesting potential reduction in transmission. Vaccine approval requires demonstrating a reduction in severe disease, which is the main focus at this stage.

Vaccine development typically takes 10 to 25 years, with the fastest recorded time in the U.S. being around 3 to 4 years. This timeline reflects the necessary clinical testing to ensure safety and efficacy. The development cycle for COVID-19 vaccines aligns closely with previous vaccine timelines, showing only modest variations. It's important for people to understand this process to alleviate concerns about the COVID-19 vaccines.

The speakers discuss the effectiveness of COVID-19 vaccines and the importance of getting vaccinated. They emphasize that vaccinated individuals are less likely to get infected, transmit the virus, or experience severe illness. They mention that vaccines slightly reduce transmission but do not completely prevent it. The speakers also mention the possibility of waning immunity over time and suggest that booster shots may be necessary. They encourage everyone to get vaccinated and highlight the goal of achieving high immunity levels to return to normalcy. The plan is for every adult to receive a booster shot.

The speakers discuss the expected mutation of the virus and the impact of vaccination. They acknowledge that as people become immunized, the virus will try to find ways to evade the vaccine. The more people are vaccinated, the more pressure is put on the virus to mutate. Some virologists warn that vaccinating the entire world with narrow immunity could lead to the emergence of superbugs. They urge for the use of the right vaccine in the right place and caution against mass vaccination during a pandemic. They argue that current interventions and mass vaccination may be causing more harm than good, driving the emergence of more infectious and potentially lethal variants.

Sir John Bell hopes for a readout early in the autumn regarding the vaccine's effectiveness. This depends on the intensity of infection and a certain number of incident cases in the controlled vaccine population. Vaccines are unlikely to completely sterilize a population, but may have an effect of, say, 60 or 70%. Regulators will need to carefully assess if the vaccine has done what it needs to do before approval. There will be a delay between the trial outcome and a decision on approval. Bell states that anything undermining the legitimacy of regulators to make independent decisions is profoundly unhelpful.

Developing an effective and safe vaccine takes around 10 to 25 years, with the current record in the US being 3 to 4 years. The timeline for COVID-19 vaccines follows a similar progression as other vaccines. There are some minor differences, but overall, the development cycle is similar. It's important for people to understand this if they have concerns about taking COVID-19 vaccines.

The speakers discuss the importance of vaccination in reducing transmission and returning to normalcy. They express confidence in the vaccines' ability to prevent illness and transmission. They emphasize the need for people to get vaccinated for their own protection and to break the chain of transmission. Vaccinated individuals are seen as dead ends for the virus, preventing further spread. However, it is mentioned that initial data on vaccine effectiveness against transmission was limited at the time of emergency use authorization. A question is raised about whether the Pfizer vaccine was tested for transmission prevention before its release, to which the response is that they had to move quickly based on scientific progress.

Vaccines are seen as magical, but expectations may need to be lowered. Pfizer's vaccine is 95% effective, but efficacy rates can fluctuate. Protection may only last a year, requiring annual shots. Moderna is working on a combined flu and COVID vaccine. The future is uncertain, but there is hope for improvement in the next 5 years.

There's a lot of discussion about when the vaccine will be available. I'm hopeful for an early autumn readout on its effectiveness, which depends on the number of infection cases in the trial population. This will help determine if the vaccinated group is protected. However, these vaccines may not completely eliminate infections; they might only be effective in about 60 to 70% of cases. Regulators will need to carefully assess the results before approval, so there will be a delay between trial outcomes and vaccine availability. It's also important to maintain the integrity of regulatory decisions, as any undermining of their legitimacy is counterproductive. Thank you for having me.

Developing a safe and effective vaccine typically takes 10 to 25 years, with the fastest in the US being around 3 to 4 years. The timeline for COVID-19 vaccines is similar to other vaccines, with some minor differences. This should reassure those hesitant about getting vaccinated.

Developing a vaccine is crucial to controlling the pandemic. Normally, it takes about five years to create a new vaccine, including testing for safety and effectiveness. However, efforts are being made to compress this timeline to around 18 months. The RNA platform shows promise in speeding up production. Ensuring a vaccine's effectiveness and safety, especially for older individuals, is challenging. We must avoid compromising safety while increasing efficacy. Decision-making regarding the use of a new vaccine will be based on limited data to expedite progress. Supporting the development of the most promising candidates, building production facilities, and conducting safety testing require a global collaborative effort. Our foundation is heavily involved in funding vaccines, including for developing countries. It's encouraging to see various medications emerging, such as Moderna, CureVac, Stamovi, and Logovac, which require investment.

AstraZeneca is confident that their vaccine is effective, but because the trial participants were young, they don't know if it prevents serious illness or death. However, their own trials show that it does deal with serious disease and hospitalization. It's important to note that the virus will mutate, but the UK has a strong genomic sequencing industry that can quickly identify mutations. The UK is also working with manufacturers to produce vaccines for new variants. This will help boost the nation's protection and future-proof the country.

Speaker 0 asked about the visibility of the medium to long-term effects of the vaccine in three to five years. Speaker 1 responded that they cannot predict how things will be in three to five years, but mentioned that 92-93% of the population will be vaccinated. Speaker 0 expressed confusion, and Speaker 1 clarified that 92-93% is the current vaccination rate. Speaker 0 raised concerns about potential side effects, but Speaker 1 reassured them that if there are any, the majority of the population would be affected. Speaker 0 remained unconvinced and expressed hesitation about getting vaccinated.

Sir John Bell anticipates a readout on the vaccine's effectiveness in early autumn, depending on infection rates. The vaccine may offer partial protection, around 60-70%, which regulators will scrutinize before approval. Any interference with regulators' independence is unhelpful.

We developed vaccines, like the Ameila vaccine, in just nine months. It's fast, considering the uncertainties surrounding vaccines. Initially, we made a mistake by claiming they protect against transmission, but they actually provide limited protection. As a result, repeated vaccinations are necessary due to their relatively short lifespan.

The speaker discusses the development, adoption, and scaling of vaccines for different variants and subvariants. They highlight the speed and extraordinary process of vaccine development. They mention the availability of manufacturing capacity, with a reference to making 100,000 doses in 2019. The speaker recalls a conversation about the need to produce $1 billion worth of vaccines in the following year due to the predicted pandemic. The discussion briefly touches on the topic of new variants and subvariants before the transcript ends.

Regulators, including the MHRA, European regulator, and World Health Organization, have found that all three COVID-19 vaccines used in the UK are safe and effective, saving thousands of lives. The vaccine rollout is going well, and the safety system is working. The AstraZeneca vaccine is not recommended for those under 30, but alternatives will be offered to ensure safety. The vaccine has not been tested on children as their risk of significant harm from COVID-19 is low. All data and side effects are being transparently shared. Face masks are recommended in hospitals, care homes, and some other environments. Vaccination not only protects individuals but also reduces transmission and brings us closer to normalcy. The UK regulator is independent and not influenced by external pressure. Leaving the EU allowed the UK to make authorization decisions faster while maintaining safety checks.